Table 1.
Characteristics of nGBM patients with and without metabolic syndrome
| Overall | With MetS | Without MetS | P-valuea | ||||
|---|---|---|---|---|---|---|---|
| N = 146 | % | n = 52 | % | n = 94 | % | ||
| Treatment groups | 0.1983b | ||||||
| Surgery only | 31 | 21.2 | 14 | 26.9 | 17 | 18.1 | |
| Surgery + radiation only | 23 | 15.8 | 6 | 11.5 | 17 | 18.1 | |
| Surgery, concurrent radiation + temozolomide | 18 | 12.3 | 9 | 17.3 | 9 | 9.6 | |
| Surgery, concurrent radiation + temozolomide, and adjuvant temozolomide | 73 | 50.0 | 23 | 44.2 | 50 | 53.2 | |
| Extent of resection | 0.5324 | ||||||
| Biopsy | 11 | 7.5 | 5 | 9.6 | 6 | 6.4 | |
| Subtotal resection | 62 | 42.5 | 24 | 46.2 | 38 | 40.4 | |
| Gross total resection | 73 | 50.0 | 23 | 44.2 | 50 | 53.2 | |
| Sex | 0.1859 | ||||||
| Male | 89 | 61.0 | 38 | 73.1 | 51 | 54.3 | |
| Female | 57 | 39.0 | 14 | 26.9 | 43 | 45.7 | |
| Race | 0.2668 | ||||||
| White | 134 | 91.8 | 49 | 94.2 | 85 | 90.4 | |
| Nonwhite | 12 | 8.2 | 3 | 5.8 | 9 | 9.6 | |
| IDH1/2 mutation | 0.1899b | ||||||
| Wild type | 43 | 29.5 | 15 | 28.8 | 28 | 29.9 | |
| Mutant | 6 | 4.1 | 4 | 7.7 | 2 | 2.1 | |
| Not tested | 97 | 66.4 | 33 | 63.5 | 64 | 68.0 | |
| MGMT promoter methylation | 1.0000 b | ||||||
| Methylated | 19 | 13.0 | 7 | 13.5 | 12 | 12.8 | |
| Unmethylated | 16 | 11.0 | 5 | 9.6 | 11 | 11.7 | |
| Not tested | 109 | 74.7 | 40 | 76.9 | 69 | 73.4 | |
| Elevated blood sugar | 5.68 × 10−10 | ||||||
| Elevated | 40 | 27.4 | 30 | 58.8 | 10 | 10.6 | |
| Not elevated | 105 | 71.9 | 21 | 41.2 | 84 | 89.4 | |
| Missing data | 1 | 0.6 | – | – | – | – | |
| Hypertension | 1.21 × 10−8 b | ||||||
| Hypertensive | 92 | 63.0 | 48 | 92.3 | 44 | 46.8 | |
| Not hypertensive | 54 | 37.0 | 4 | 7.7 | 50 | 53.2 | |
| Missing data | 0 | 0.0 | – | – | – | – | |
| Triglycerides | 4.95 × 10−17 | ||||||
| Increased triglycerides | 52 | 35.6 | 42 | 80.8 | 10 | 10.9 | |
| Triglycerides not increased | 92 | 63.0 | 10 | 19.2 | 82 | 89.1 | |
| Missing data | 2 | 1.4 | – | – | – | – | |
| HDLC | 2.10 × 10−17 | ||||||
| Decreased HDLC | 57 | 39.0 | 44 | 88.0 | 13 | 14.4 | |
| No decreased HDLC | 83 | 56.8 | 6 | 12.0 | 77 | 85.6 | |
| Missing data | 6 | 4.1 | – | – | – | – | |
| Obesity | 4.17 × 10−6 | ||||||
| Obese | 44 | 30.1 | 28 | 53.8 | 16 | 17.0 | |
| Not obese | 101 | 69.2 | 24 | 46.2 | 77 | 81.9 | |
| Missing data | 1 | 0.7 | – | – | 1 | 0.1 | |
| Age, y, mean | 64.2 | 66.2 | 63.1 | 0.1391 | |||
| Postoperative KPS (median) | 70 | 70 | 70 | 0.1687c | |||
| Median survival, mo (95% CI) | 11.3 (9.3–12.8) | 7.7 (5.9–12.4) | 12.70 (10.8–16.9) | 0.224 | |||
| Median survival [surgery, radiation + temozolomide only, adjusted for age], mo (95% CI) | 14.0 (12.8–19.7) | 12.4 (9.5–14.2) | 17.9 (15.0–22.1) | 0.1847d | |||
| Median TTP, mo (95% CI) | 11.0 (10.0–13.4) | 11.8 (8–..) | 11.0 (10.0–13.4) | 0.347 | |||
| Median TTP [surgery, radiation + temozolomide only, adjusted for age], mo (95% CI) | 10.3 (8.6–13.4) | 10.3 (8.0–..) | 11.0 (9.3–13.4) | 0.7000 d | |||
aTest of significance between MetS groups.
bFisher’s exact test.
cWilcoxon rank sum test.
d P-value for trait in Cox proportional hazards model adjusted for age at diagnosis.
**Confidence interval (CI) cannot be calculated.